ERSPC publitseeritud leiud (veel)
Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Ballentine Carter H, Veltri RW. Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 2009; 15 (23): 7316-21.
Stephan et al. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 2009; 69:198-207.
Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda, MG, Thompson IM, Chan DW.
[-2]Proenzyme prostate specific antigen for prostate cancer detection: A National Cancer Institute Early Detection Research Network validation study. J Urol 2008; 180, 539-543.
Bangma CH, Roemeling S, Schröder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007.
Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schröder FH.
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007.